| __timestamp | Halozyme Therapeutics, Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 12665000 |
| Thursday, January 1, 2015 | 29245000 | 20202000 |
| Friday, January 1, 2016 | 33206000 | 32407000 |
| Sunday, January 1, 2017 | 31152000 | 35219000 |
| Monday, January 1, 2018 | 10136000 | 36386000 |
| Tuesday, January 1, 2019 | 45546000 | 43081000 |
| Wednesday, January 1, 2020 | 43367000 | 39330000 |
| Friday, January 1, 2021 | 81413000 | 43283000 |
| Saturday, January 1, 2022 | 139304000 | 48316000 |
| Sunday, January 1, 2023 | 192361000 | 54634000 |
Data in motion
In the competitive landscape of biotechnology and medical devices, cost efficiency is paramount. Over the past decade, Halozyme Therapeutics, Inc. and MiMedx Group, Inc. have showcased contrasting trajectories in their cost of revenue. From 2014 to 2023, Halozyme's cost of revenue surged by approximately 747%, peaking in 2023. This reflects their aggressive expansion and investment in innovative therapies. In contrast, MiMedx Group's cost of revenue grew by about 331% during the same period, indicating a more conservative growth strategy.
These trends highlight the strategic differences between the two companies, offering investors insights into their operational efficiencies and market strategies.
Cost of Revenue Trends: Novo Nordisk A/S vs MiMedx Group, Inc.
Cost of Revenue Trends: Amgen Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Halozyme Therapeutics, Inc.
Catalent, Inc. vs Halozyme Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and HUTCHMED (China) Limited
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Celldex Therapeutics, Inc. vs MiMedx Group, Inc.